Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine
bit.bio

Where: B16/B9
bit.bio combines the concepts of cellular reprogramming and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines

This is possible with our precision cellular reprogramming technology, opti-ox™ - a core component of our Cell Identity Coding Platform. opti-ox is a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently at scale through direct reprogramming of stem cells.

Under our ioCells brand we already have a wide range of wild type and disease model cells available for research and drug discovery including nerve cells, immune cells and muscle cells. Our portfolio is expanding at pace and all our cells are powered by opti-ox so are consistent, easy to use and highly defined.

We are currently building a clinical pipeline of cell therapies. Our areas of development are liver, immune and metabolic.
Tel: 01223 787 297
Address: The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge
Website: https://bit.bio/
Email: info@bit.bio

Presentations at Drug Discovery 2021 After the Storm: Re-connect, Re-invent, Re-imagine

Staff Attending

Jeremy Anton
bit.bio
Kam Dhaliwal
SVP Alliance Management
bit.bio
Dr Tonya Frolov
Product Manager
bit.bio
Dr Sara Gomes
bit.bio
Miss Roisin Nicoll
Sales Manager
Bit Bio
Zoe Nilsson
bit.bio
Tony Oosterveen
bit.bio
Dr Vin Raninga
bit.bio
Dr Marta Rucka
bit.bio